Table 3 GEE analysis results of the 536 chronic hepatitis C patients who underwent anti-hepatitis C virus therapy.

Variants	PAI-1 (ng/ml)
Variants	95% CI of estimated exp (β) [Estimated exp. (β)]	p-values
Sex (female)	0.214~0.848 (0.426)	0.015*
Age	0.939~1.012 (0.975)	0.181
BMI	1.043~1.296 (1.163)	0.007*
Therapy intervention (without)	0.012~0.155 (0.043)	<0.001*
Therapy duration	0.841~1.346 (1.064)	0.553
SVR	0.202~1.514 (0.552)	0.249
HCV genotype	0.59~2.354 (1.178)	0.642
HCV RNA (Log10 IU/ml)	0.683~1.281 (0.935)	0.676
HOMA-IR	1.003~1.066 (1.034)	0.003*
ALT (U/L)	0.994~1.004 (0.999)	0.704
APRI	1.038~1.1 (1.069)	<0.001*
hsCRP (mg/dL)	0.941~1.279 (1.097)	0.235
WBC count (10³/μL)	0.982~1.253 (1.235)	0.07
Platelets count (10³/μL)	1.018~1.033 (1.026)	<0.001*
Hepatic steatosis (yes)	0.569~2.014 (1.07)	0.833
Liver cirrhosis (yes)	0.596~3.476 (1.495)	0.391
TC (mg/dL)	0.972~0.998 (0.985)	0.023*
TGs (mg/dL)	1.002~1.006 (1.004)	0.001*
PAI-1 (ng/ml)	NA	NA
BNP (Log₁₀ pg/mL)	0.189~2.627 (0.704)	0.602
Homocysteine (μmol/L)	0.234~3.86 (1.234)	0.885
eGFR	1.001~1.045 (1.023)	0.042*
PAI-1-rs1799889 (4 G/4 G genotype)	1.69~4.09 (2.63)	<0.001*
IFNL3-rs12979860 (CC genotype)	1.18~4.18 (2.22)	0.013*

Estimates of exp. (β), 95% confidence interval (CI) of exp. (β) and p-values for the variants that predicted PAI-1 longitudinally. GEE: generalized estimating equation; CI: confidence interval; OR: odds ratio; *p < 0.05; NA, not accessible; SVR: sustained virological response; BMI: body mass index; Log: logarithmic; HOMA-IR: homeostasis model assessment-estimated insulin resistance; ALT: alanine aminotransferase; APRI: aspartate aminotransferase to platelet ratio index; hsCRP: high sensitivity C-reactive protein; WBC: white blood cells; TC: total cholesterol; TGs: triglycerides; PAI-1: plasminogen activator inhibitor-1; BNP: brain natriuretic peptide; eGFR: estimated glomerular filtration rate; IFNL3: interferon-λ3.

Quick links

Search